Compare Stocks: RNAZ, TNYA, OKUR, and CNTB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTB Connect Biopharma	$2.21 -0.9%	$2.27	$1.23 ▼ $3.82	$139.16M	-0.23	297,650 shs	350,685 shs
OKUR OnKure Therapeutics	$3.61 -4.7%	$4.16	$2.23 ▼ $5.38	$145.84M	0.3	250,687 shs	33,333 shs
RNAZ TransCode Therapeutics	$2.14 -1.8%	$5.50	$1.83 ▼ $20.99	$36.23M	1.24	126,803 shs	782,673 shs
TNYA Tenaya Therapeutics	$0.68 -1.0%	$0.76	$0.53 ▼ $2.35	$153.13M	2.83	3.56 million shs	784,300 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTB Connect Biopharma	0.00%	-5.51%	+10.40%	-4.70%	+8.25%
OKUR OnKure Therapeutics	0.00%	-3.81%	-0.79%	-9.76%	+37.82%
RNAZ TransCode Therapeutics	0.00%	-24.04%	-52.19%	-59.55%	-77.60%
TNYA Tenaya Therapeutics	0.00%	-1.03%	-6.78%	-20.68%	-38.93%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTB Connect Biopharma	$2.21 -0.9%	$2.27	$1.23 ▼ $3.82	$139.16M	-0.23	297,650 shs	350,685 shs
OKUR OnKure Therapeutics	$3.61 -4.7%	$4.16	$2.23 ▼ $5.38	$145.84M	0.3	250,687 shs	33,333 shs
RNAZ TransCode Therapeutics	$2.14 -1.8%	$5.50	$1.83 ▼ $20.99	$36.23M	1.24	126,803 shs	782,673 shs
TNYA Tenaya Therapeutics	$0.68 -1.0%	$0.76	$0.53 ▼ $2.35	$153.13M	2.83	3.56 million shs	784,300 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTB Connect Biopharma	0.00%	-5.51%	+10.40%	-4.70%	+8.25%
OKUR OnKure Therapeutics	0.00%	-3.81%	-0.79%	-9.76%	+37.82%
RNAZ TransCode Therapeutics	0.00%	-24.04%	-52.19%	-59.55%	-77.60%
TNYA Tenaya Therapeutics	0.00%	-1.03%	-6.78%	-20.68%	-38.93%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTB Connect Biopharma	2.75	Moderate Buy	$7.43	239.20% Upside
OKUR OnKure Therapeutics	2.25	Hold	$17.50	384.76% Upside
RNAZ TransCode Therapeutics	1.00	Sell	N/A	N/A
TNYA Tenaya Therapeutics	2.86	Moderate Buy	$4.00	486.94% Upside

Current Analyst Ratings Breakdown

Latest RNAZ, TNYA, OKUR, and CNTB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	CNTB Connect Biopharma	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$7.00
8/14/2026	OKUR OnKure Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$14.00
7/28/2026	OKUR OnKure Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	TNYA Tenaya Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/20/2026	OKUR OnKure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$21.00
7/17/2026	RNAZ TransCode Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/9/2026	CNTB Connect Biopharma	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
7/2/2026	TNYA Tenaya Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/30/2026	CNTB Connect Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
6/26/2026	CNTB Connect Biopharma	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral ➝ Overweight	$7.00
6/26/2026	CNTB Connect Biopharma	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral ➝ Overweight	$7.00

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTB Connect Biopharma	$60K	2,298.41	N/A	N/A	$0.75 per share	2.92
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	$4.11 per share	N/A
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	$11.27 per share	N/A
TNYA Tenaya Therapeutics	$1.34M	114.47	N/A	N/A	$0.57 per share	1.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTB Connect Biopharma	-$55.48M	-$1.19	N/A	N/A	N/A	N/A	-165.41%	-121.58%	11/11/2026 (Estimated)
OKUR OnKure Therapeutics	-$59.52M	-$3.50	N/A	N/A	N/A	N/A	-49.01%	-45.77%	11/5/2026 (Estimated)
RNAZ TransCode Therapeutics	-$34.66M	-$52.37	N/A	N/A	N/A	N/A	-875.35%	-37.46%	11/18/2026 (Estimated)
TNYA Tenaya Therapeutics	-$90.60M	-$0.53	N/A	N/A	N/A	N/A	-83.75%	-66.53%	11/11/2026 (Estimated)

Latest RNAZ, TNYA, OKUR, and CNTB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	RNAZ TransCode Therapeutics	N/A	-$7.17	N/A	-$7.17	N/A	N/A
8/12/2026	Q2 2026	CNTB Connect Biopharma	-$0.3149	-$0.27	+$0.0449	-$0.27	$0.74 million	$2.75 million
8/5/2026	Q2 2026	TNYA Tenaya Therapeutics	-$0.0683	-$0.20	-$0.1317	-$0.20	$10.00 million	$1.11 million
8/4/2026	Q2 2026	OKUR OnKure Therapeutics	-$0.5350	-$0.31	+$0.2250	-$0.31	$0.17 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	N/A
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTB Connect Biopharma	0.01	2.37	2.37
OKUR OnKure Therapeutics	N/A	26.75	26.75
RNAZ TransCode Therapeutics	N/A	1.97	1.97
TNYA Tenaya Therapeutics	N/A	4.52	4.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTB Connect Biopharma	58.72%
OKUR OnKure Therapeutics	90.98%
RNAZ TransCode Therapeutics	N/A
TNYA Tenaya Therapeutics	90.54%

Insider Ownership

Company	Insider Ownership
CNTB Connect Biopharma	22.60%
OKUR OnKure Therapeutics	2.17%
RNAZ TransCode Therapeutics	0.10%
TNYA Tenaya Therapeutics	2.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTB Connect Biopharma	110	62.97 million	48.74 million	Optionable
OKUR OnKure Therapeutics	N/A	40.40 million	39.52 million	N/A
RNAZ TransCode Therapeutics	9	16.93 million	16.91 million	Not Optionable
TNYA Tenaya Therapeutics	110	224.23 million	218.56 million	Optionable

RNAZ, TNYA, OKUR, and CNTB Headlines

Recent News About These Companies

Tenaya Therapeutics (NASDAQ:TNYA) Stock Rating Lowered by Wall Street Zen

August 29 at 1:24 AM | americanbankingnews.com

Tenaya Therapeutics (NASDAQ:TNYA) Cut to Strong Sell at Wall Street Zen

August 29 at 1:23 AM | marketbeat.com

1,555,500 Shares in Tenaya Therapeutics, Inc. $TNYA Purchased by ADAR1 Capital Management LLC

August 26, 2026 | marketbeat.com

Empery Asset Management LP Takes $2.86 Billion Position in Tenaya Therapeutics, Inc. $TNYA

August 22, 2026 | marketbeat.com

Faraz Ali Sells 22,232 Shares of Tenaya Therapeutics (NASDAQ:TNYA) Stock

August 18, 2026 | insidertrades.com

Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301

August 18, 2026 | marketbeat.com

Tenaya Therapeutics (NASDAQ:TNYA) CEO Sells $15,784.72 in Stock

August 17, 2026 | marketbeat.com

GSA Capital Partners LLP Makes New $1.97 Million Investment in Tenaya Therapeutics, Inc. $TNYA

August 17, 2026 | marketbeat.com

Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

August 14, 2026 | seekingalpha.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Recommendation of "Moderate Buy" by Brokerages

August 11, 2026 | marketbeat.com

Renaissance Technologies LLC Increases Stock Holdings in Tenaya Therapeutics, Inc. $TNYA

August 10, 2026 | marketbeat.com

HC Wainwright Has Positive Outlook of TNYA FY2026 Earnings

August 10, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA) and Viridian Therapeutics (VRDN)

August 7, 2026 | theglobeandmail.com

Q3 Earnings Forecast for TNYA Issued By HC Wainwright

August 7, 2026 | marketbeat.com

Tenaya Therapeutics (NASDAQ:TNYA) Issues Quarterly Earnings Results

August 5, 2026 | marketbeat.com

Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 5, 2026 | globenewswire.com

Tenaya Therapeutics (TNYA) to Post Earnings on Wednesday

August 5, 2026 | marketbeat.com

Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

August 4, 2026 | globenewswire.com

Cours Tenaya Therapeutics, Inc.

July 29, 2026 | zonebourse.comZ

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

July 14, 2026 | globenewswire.com

Tenaya Therapeutics (TNYA) Slides to $0.86 as Bearish Pressure Tests Support - Order Block

July 13, 2026 | donanimhaber.comD

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAZ, TNYA, OKUR, and CNTB Company Descriptions

Connect Biopharma NASDAQ:CNTB

$2.21 -0.02 (-0.90%)

As of 12:51 PM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

OnKure Therapeutics NASDAQ:OKUR

$3.61 -0.18 (-4.75%)

As of 12:51 PM Eastern

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

TransCode Therapeutics NASDAQ:RNAZ

$2.14 -0.04 (-1.83%)

As of 12:49 PM Eastern

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

Tenaya Therapeutics NASDAQ:TNYA

$0.68 -0.01 (-1.04%)

As of 12:51 PM Eastern

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNAZ, TNYA, OKUR, and CNTB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNAZ, TNYA, OKUR, and CNTB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNAZ, TNYA, OKUR, and CNTB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAZ, TNYA, OKUR, and CNTB Company Descriptions

Connect Biopharma NASDAQ:CNTB

OnKure Therapeutics NASDAQ:OKUR

TransCode Therapeutics NASDAQ:RNAZ

Tenaya Therapeutics NASDAQ:TNYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNAZ, TNYA, OKUR, and CNTB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNAZ, TNYA, OKUR, and CNTB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNAZ, TNYA, OKUR, and CNTB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAZ, TNYA, OKUR, and CNTB Company Descriptions

Connect Biopharma NASDAQ:CNTB

OnKure Therapeutics NASDAQ:OKUR

TransCode Therapeutics NASDAQ:RNAZ

Tenaya Therapeutics NASDAQ:TNYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools